AIM ImmunoTech (NYSE:AIM) Given New $1.00 Price Target at Maxim Group

by · The Markets Daily

AIM ImmunoTech (NYSE:AIM – Free Report) had its target price reduced by Maxim Group from $2.00 to $1.00 in a report published on Tuesday, Benzinga reports. They currently have a buy rating on the stock.

Separately, Ascendiant Capital Markets cut their price target on shares of AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd.

Read Our Latest Report on AIM

AIM ImmunoTech Stock Up 3.2 %

Shares of NYSE AIM opened at $0.27 on Tuesday. AIM ImmunoTech has a 1 year low of $0.21 and a 1 year high of $0.62. The firm has a 50-day simple moving average of $0.30 and a two-hundred day simple moving average of $0.36. The company has a market cap of $13.84 million, a P/E ratio of -0.42 and a beta of -0.39. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.17 and a quick ratio of 1.17.

AIM ImmunoTech (NYSE:AIM – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.03) earnings per share (EPS) for the quarter. The business had revenue of $0.05 million for the quarter. AIM ImmunoTech had a negative return on equity of 269.04% and a negative net margin of 13,952.74%. Research analysts anticipate that AIM ImmunoTech will post -0.35 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in AIM ImmunoTech stock. Armistice Capital LLC purchased a new position in shares of AIM ImmunoTech Inc. (NYSE:AIM – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned approximately 7.92% of AIM ImmunoTech at the end of the most recent quarter. Institutional investors own 12.02% of the company’s stock.

About AIM ImmunoTech

(Get Free Report)

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).

Featured Articles